Company News | Jacobio Pharma

42 press releases in total

2023

Aug 30, 2023

Jacobio Pharma Announces 2023 Interim Results

[More]
Aug 7, 2023

Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer

[More]
Jul 21, 2023

Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference

[More]
Jul 4, 2023

Jacobio Receives CDE Approval for Glecirasib’s Pancreatic Cancer Pivotal Study in China

[More]
Jun 29, 2023

Jacobio Pharma Presents Clinical Results of Glecirasib in Colorectal Cancer

[More]
Jun 8, 2023

Jacobio Pharma Receives IND Approval for PARP7 Inhibitor JAB-26766 in China

[More]
Apr 18, 2023

Jacobio Pharma Presented Data of Three Preclinical Studies at the 2023 AACR Annual Meeting

[More]
Apr 4, 2023

Jacobio Pharma Receives IND Approval for LIF mAb JAB-BX300 in China

[More]
Mar 22, 2023

Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer

[More]
Mar 22, 2023

Jacobio Pharma Announces 2022 Annual Results

[More]
Mar 17, 2023

Jacobio Receives IND Approval for GUE Inhibitor JAB-24114 in China

[More]
Mar 15, 2023

Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting

[More]
Jan 8, 2023

Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S.

[More]

2022

Pages